Shots:

• CSL to acquire all the outstanding shares of Vifor Pharma for $179.25/share making a total equity value of $11.7B representing a premium of 40% to the last closing price of Vifor. The transaction is expected to complete in mid-2022
• The acquisition bolsters CSL's 2030 strategy & expands its leadership positions including CSL's business model. The acquisition expands CSL's portfolio with the addition of 10 commercialized products for the treatment of renal disease and iron deficiency
• Additionally, Vifor will use CSL’s capabilities to bring more products to patients & will also accelerate its growth in cardiovascular-metabolic, renal, and transplant

Ref: PR Newswire | Image: Vifor